News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.
Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry. The tumultuous ...
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...